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Pneumococcal disease is now the leading cause of vaccine-preventable bacterial disease
in children worldwide. Although a pneumococcal polysaccharide vaccine has been
available for over three decades, its use has been limited due to poor immunogenicity
in the most vulnerable children, aged less than 2 years. The prevalence of pneumococcal
disease worldwide and the alarming global escalation of multiresistant strains of
Streptococcus pneumoniae (pneumococcus) during the past decade have provided the
impetus for the development and application of a new pneumococcal vaccine. The
outstanding success of Haemophilus inﬂuenzae type b (Hib) conjugate vaccine in the
control of invasive Hib disease is a reason to be optimistic that the pneumococcal
conjugate vaccines will achieve similar results for the control of invasive pneumococcal
disease. Remarkable efﬁcacy against invasive pneumococcal disease with a seven-valent
pneumococcal conjugate vaccine was demonstrated in infants and toddlers in the USA,
and in February 2000 the ﬁrst pneumococcal conjugate vaccine was licensed. Licensure
and widespread use is likely to follow in other countries in which there is a need and the
means to afford this live-saving vaccine. Active disease surveillance must be sustained
globally, while active research, development of other multivalent conjugate formulations
and the search for new candidate protein-based vaccines are in progress.
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INTRODUCTION
Streptococcus pneumoniae has provided a remark-
able biological model for the understanding of
bacterial pathogenesis for over a century, but
nevertheless, its conquest has eluded biomedical
researchers until very recently [1]. From conserva-
tive estimates, the pneumococcus is thought to be
responsible for at least 1 million deaths in children
aged less than 5 years, worldwide, annually [2,3].
The recent application of Haemophilus inﬂuenzae
type 1 (Hib) conjugate vaccines and the subse-
quent remarkable decline in the incidence of inva-
siveHib disease has further highlighted the impact
of invasive pneumococcal diseases. The pneumo-
coccus is now arguably the leading cause of bac-
terial meningitis in children in most settings and
the leading cause of vaccine-preventable bacterial
disease in children worldwide.
Treatment of pneumococcal disease has become
more expensive and complex during the past dec-
ade, as the prevalence of multiresistant strains has
increased. The prevalence of penicillin-resistant
pneumococcal isolates in the UK increased from
4.2% in 1992 to 12.6% in 1999 [4]. In other countries,
the incidence has also been on the rise. The pre-
valence of penicillin-resistant strains varies from
43% in South Africa, to 49% in the USA, to 53% in
France, to 60% in Spain, to 79% in Korea [5].
Although there has been no demonstrable parallel
increase in mortality from infection with drug-
resistant pneumococcal infections, cure clearly
involves expensive antibiotics and longer duration
of hospitalization.
Antibiotic use has been consistently associated
with carriage of antibiotic-resistant strains of
pneumococci and the subsequent development
of invasive disease. Suppression of upper respira-
tory tract organisms by antibiotic treatment
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removes the competing ﬂora and renders the host
susceptible to acquisition of strains that are resis-
tant to the antibiotics [6]. Despite the rapidly
evolving technology for the development of new
and highly potent antimicrobials, it is now clear
that the battle against the pneumococcus can only
be won by prevention of infections through the
application of potent vaccines.
This update reviews the burden of pneumococ-
cal disease, and the development and application
of the new conjugate vaccines in the control of
disease, and discusses potential strategies for the
control of pneumococcal disease in highly suscep-
tible but resource-deprived populations.
THE PNEUMOCOCCUS
S. pneumoniae (pneumococcus) is an encapsulated
Gram-positive bacterium. The capsule consists of
polysaccharides, with characteristic chemical
structures, which form the basis of serogroups
and serotypes. There are currently over 90 recog-
nized serotypes [7]. The polysaccharide capsule
constitutes amajor virulence factor, and antibodies
directed against it facilitate the opsonization of the
bacteria for phagocytosis. These antibodies are
critical in protection against pneumococcal infec-
tions.
The pneumococcus is a common commensal of
the respiratory tract, particularly in children, in
whom colonization rates may be in excess of 90%
in some developing country communities [8–10].
Nasopharyngeal colonization is the initial event
from which mucosal and invasive pneumococcal
infection develops and is also the nidus of pneu-
mococcal transmission [11].
The different pneumococcal serotypes vary in
prevalence and virulence, depending on a multi-
tude of factors, including host, age, region and
country. Their distribution is temporal and varies
by geographic location, and a few serotypes pre-
dominantly cause disease in children [12]. In addi-
tion, the immune response is generally serotype
speciﬁc. Knowledge of the prevalent serotypes
and epidemiology of disease in a given population
is crucial to the development and implementation
of any vaccination program.
DISEASE BURDEN
The pneumococcus is responsible for a broad
spectrum of diseases, some of which are invasive
and others non-invasive, affecting only mucosal
surfaces. The highest rates of invasive pneumo-
coccal disease (e.g. bacteremia, meningitis or infec-
tion of other sterile body sites) occur in young
children, aged less than 2 years [13,14].
Invasive disease
In the USA and other developed countries, the
most commonly recognized form of invasive dis-
ease is bacteremia, which accounts for about 70%
of invasive disease. Following the decline of inva-
sive Hib disease, the pneumococcus is now the
most common cause of bacterial meningitis. In the
USA, prior to the introduction of pneumococcal
conjugate vims it accounted for an estimated 3000
cases of meningitis annually [14,15]. Recent data
from Scotland have revealed that almost 40% of
bacterial meningitis in patients under the age of
5 years is caused by the pneumococcus [16].
Furthermore, complications and long-term seque-
lae are more frequent with pneumococcal menin-
gitis than with other forms of bacterial meningitis
[17]. This observation has been conﬁrmed in other
communities where there is a high prevalence of
bacterial meningitis [18].
Non-invasive disease syndromes
Otitis media
Otitis media is a source of substantial morbidity in
children and perhaps the most common reason for
pediatric outpatient consultations. However, since
it is caused by a wide variety of organisms, etio-
logic diagnosis can only be conﬁdently made by
tympanostomy and bacteriologic examination of
middle ear ﬂuid. Unfortunately, this procedure is
not routinely performed, and, consequently, true
estimates of the burden of otitis media attributable
to the pneumococcus are difﬁcult to obtain. It is
estimated that the pneumococcus is responsible
for at least 25–50% of all cases of bacterial otitis
media [19,20]. In the UK, it is estimated that 14% of
children have acute otitis media during the ﬁrst
year of life, 18% in the second and 12% in the third;
this implies that S. pneumoniaemay be responsible
for 180 000–350 000 episodes of disease annually in
children aged less than 5 years [21].
In the USA, acute otitis media accounts for over
24 million outpatient consultations each year and
contributes substantially to theburdenof childhood
morbidity and parental absence from work [22,23].
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From the perspective of pneumococcal dis-
ease, in the developed countries otitis media is
the least severe but the most prevalent, and con-
sequently incurs the largest component of health-
care costs and accounts for the largest morbidity.
However, in less developed countries, the bur-
den of otitis media is less well perceived, and
more concern is generated by the more ‘dramatic’
forms of disease, such as meningitis and pneu-
monia.
Acute lower respiratory infections
Respiratory infections due to this organism are
most prevalent in young children and the elderly.
However, the true burden of disease attributable
to the pneumococcus is difﬁcult to estimate,
because lower respiratory tract illnesses in general
aremanaged empiricallywith antibiotic treatment,
with diagnosis often based on clinical signs, some-
times with radiologic conﬁrmation but seldom
with bacteriologic conﬁrmation. Most studies that
have attempted to quantify the burden of disease
have been retrospective. In general, the incidence
of respiratory tract infections varies widely, but
has been highest in poor, developing countries. In
the USA, the pneumococcus was responsible for
over 500 000 cases of pneumonia per year [15],
until the implementation of routine vaccination.
In the UK, a study of hospital admissions in 1994–
95 reported estimates for different clinical cate-
gories of lower respiratory tract infections such as
bronchopneumonia, lobar pneumonia and unspe-
ciﬁed pneumonia, as 36, 104 and 85 per 100 000,
respectively, in children aged less than 5 years [24].
In Finland, the incidence of community-acquired
pneumonia in 1981–82 was estimated as 36 per
1000 children aged less than 5 years [25].
In many developing countries, the etiology of
childhood pneumonia is not known and little
information is available on the relative import-
ance of bacterial and viral agents of pneumonia
in these communities [26]. In the Gambia, an active
hospital-based disease surveillance program was
undertaken during the efﬁcacy trial of a protein
conjugate Hib vaccine study (1994–97). The inci-
dences of pneumococcal disease were 224 per
100 000 child years among children aged 2–
11months, 139 per 100 000 among children aged
12–23months, and 82 per 100 000 among children
aged 24–35months. Pneumoniawas themost com-
mon form of invasive pneumococcal disease
observed (75.5% of patients) [27].
Studies that have attempted to ascertain the etio-
logic cause of pneumonia in children have largely
utilized serology and bacterial culture and have
estimated that 13–38% of cases of community-
acquired pneumonia in children are due to S.
pneumoniae [28–31]. However, studies that have,
in addition, utilized bacterial studies of lung aspi-
rates from Africa suggest that this diagnostic
technique improves the diagnostic yield for S.
pneumoniae by an additional 50% [32,33]. The pro-
cedure is safe, is less uncomfortable than broncho-
scopy,andprovidesreliablediagnostic information.
Technically, it is nomore difﬁcult than thoracocen-
tesis, and patient acceptance is good. The proce-
dure is not widely used because of the possible
risks of pneumothorax or hemoptysis, which are
fortunately very rare. The beneﬁts seem to far
outweigh the risks [34].
PNEUMOCOCCAL
POLYSACCHARIDE VACCINE
Once the signiﬁcance of capsular serotypes was
understood, vaccine development was more
focused on developing vaccines with the prevalent
serotypes. Polyvalent vaccines were manufac-
tured. These contain the individually extracted
puriﬁed capsular polysaccharides, which are com-
bined into the ﬁnal product. The ﬁrst successful
clinical trial of a vaccine with four serotypes was
demonstrated by MacLeod among military
recruits in 1945. This was followed by a trial of
a hexavalent pneumococcal polysaccharide vac-
cine. Unfortunately, interest in further develop-
ment waned with the advent of penicillin, which
was thought to be the ‘magic bullet’ for the pneu-
mococcus. After nearly a decade, it became clear
that the pneumococcus was still a problem, and
research into the development of polyvalent pneu-
mococcal polysaccharide vaccines resumed. A 14-
valent polysaccharide vaccine was licensed in
1977. This was soon followed by the 23-valent
vaccine, which was licensed internationally in
1981 (reviewed in ref. [1]).
The 23-valent capsular polysaccharide vaccine
is not effective in children less than 2 years old, the
most vulnerable age group for invasive pneumo-
cocal disease. The poor immunologic response to
polysaccharide antigens in this age group is due to
the lack of T-cell involvement, which is a prere-
quisite for high-level antibody response and
induction of immunologic memory [35,36]. The
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immune response can be enhanced by the cou-
pling of the polysaccharide antigen to a protein
carrier that can be processed and presented to T-
cells bearing speciﬁc receptors for the protein
complex. The T-cells exposed to the polysacchar-
ide–protein conjugate are able to promote vigor-
ous antigen-speciﬁc B-cell proliferation and
memory maturation [35,36]. This approach of
polysaccharide–protein conjugation was used
with great success for the development of the
now widely used Hib vaccine.
PNEUMOCOCCAL CONJUGATE
VACCINES
Vaccine composition
The development of a protein conjugate vaccine
for the pneumococcus has involved the selection of
a few prevalent serotypes, and these have been
individually coupled to an immunogenic carrier
protein. The initial effort for the development of
this vaccine has been largely based in the USA, so
the vaccine formulations have been based on epi-
demiologic data from the USA [37].
Different proteins have been selected for con-
jugation, and these include diphtheria and tetanus
toxoids, the meningococcal outer-membrane com-
plex, and diphtheria protein CRM197. Several vac-
cine formulations incorporating between four and
11 pneumococcal capsular polysaccharide types
have been subjected to safety and immunogenicity
studies. The immune responses to the pneumo-
coccal polysaccharide and the interaction with
other vaccines have varied considerably, depend-
ing on the carrier protein used.
The seven-valent pneumococcal conjugate vac-
cine (Prevnar) includes seven puriﬁed capsular
polysaccharides of S. pneumoniae, each coupled
to a non-toxic diphtheria protein analog (cross-
reactive material, CRM). The vaccine contains
approximately 2 mg each of capsular polysacchar-
ide from serotypes 4, 9V, 14, 19F and 23F, and
oligosaccharide from 18C, 4 mg of serotype 6B,
20 mg of the carrier protein CRM197, and
0.125mg of aluminum in each 0.5-mL dose as an
aluminum phosphate adjuvant.
During the period 1978–94, these serotypes
accounted for 86% of bacteremia cases, 83% of
meningitis cases and 65% of otitis media cases
in children aged less than 6 years of age in the
USA [37]. Assuming equivalent efﬁcacy, the cover-
age conferred by this formulation will vary con-
siderably from one country to another because of
the geographic and epidemiologic differences in
serotype distribution and disease pattern. For
example, serogroups in the seven-valent formula-
tion [4,6,9,14,18,19,23] cause 70–88% of invasive
pneumococcal disease in young children in the
USA and Canada, Europe, Oceania and Africa.
However, this same combination accounts for less
than 65% of disease in Latin America and Asia.
Serogroups in the nine-valent formulation, which
incorporates components of the seven-valent vac-
cine and in addition serotypes 1 and 5, cause 80–
90% of pneumococcal disease in most regions of
the world except Asia (66%). Other serotypes not
included in the current vaccine formulations tend
to cause disease more frequently in older children
and adults [12].
Safety
Since the development of protein conjugate vac-
cines, several studies have evaluated the safety of
different formulations, including two-, ﬁve-,
seven- and nine-valent formulations. Prior to
licensure, over 22 000 children received the vac-
cines, and there have been no reports of severe
systemic or life-threatening reactions attributable
to the vaccine [38–46]. Currently, there are several
pneumococcal polysaccharide–protein conjugate
vaccines in various phases of clinical trials with
children. In general, these vaccines have demon-
strated a good safety proﬁle. The common adverse
reactions have been limited to local swelling or
redness at the site of injection, and this is self-
limiting, resolving within a few days of vaccina-
tion. These local reactions are signiﬁcantly milder
than those observed with previously licensed vac-
cines such as the diphtheria–pertussis–tetanus
(DPT) (whole cell) vaccines [45]. Rate, types and
severity of the adverse events associated with the
seven-valent pneumococcal conjugate vaccine
during the Kaiser Permanente studies were accep-
table [43,47].
Immunogenicity
Several studies have evaluated immunogenicity in
the context of local immunization practices in
different populations [44–47]. The majority of chil-
dren have been offered three doses of the vaccine
after the age of 6weeks or greater at monthly or bi-
monthly intervals, and in some instances, a booster
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dose at 15–18months of age. Some of these studies
have also demonstrated the induction of immu-
nologic memory with the use of pneumococcal
polysaccharide after the primary series [48,49].
Although much work has been done on stan-
dardizing the laboratory technique for the deter-
mination of antibody concentration in serum, it is
still not known what concentration of serotype-
speciﬁc antibody confers protection. It also
remains contentious whether a given concentra-
tion will confer protection against the different
forms of non-invasive (mucosal) and invasive
pneumococcal disease [50]. In general, a cue has
been taken from antibody responses to the Hib
conjugate vaccine, and this has been applied to the
pneumococcus. The importance of antibody qual-
ity, and not just quantity, has been recognized in
determining protection. In some of these studies,
the opsonophagocytic activity of vaccine-induced
antibodies has been demonstrated [48,51]. In addi-
tion, secretory antibodies in saliva [52,53] and the
impact of vaccination on nasopharyngeal carriage
have been demonstrated in some studies [44,46,
54]. The vaccine has the capacity to reduce the
incidence of nasopharyngeal carriage of serotypes
contained in the vaccine.
Vaccine efficacy
These very encouraging reports led to the ﬁrst
large-scale efﬁcacy trial in the USA, and there
are now several other studies evaluating the efﬁ-
cacy of the same vaccine or similar formulations
against different endpoints in different popula-
tions.
Efficacy against invasive disease
The ﬁrst efﬁcacy trial for a pneumococcal conju-
gate vaccine commenced in October 1995 and was
completed in August 1998; the results led to the
licensure of the seven-valent pneumococcal con-
jugate vaccine in the USA in February 2000. In a
randomized, controlled study by the Northern
California Kaiser Permanente group, 37 830 infants
were assigned to either a seven-valent pneumo-
coccal conjugate vaccine or a control vaccine
(meningococcal conjugate vaccine), and all chil-
dren were monitored for acute illness consistent
with invasive pneumococcal disease [47]. Vaccina-
tion was administered at ages 2, 4, 6 and 12–
15months, concurrently with routine licensed vac-
cines. When all cases of invasive disease were
evaluated, there were 40 fully vaccinated cases
caused by vaccine serotypes, of which 39 cases
occurred in controls, for an efﬁcacy of 97.4% (95%
CI¼ 82.7–99.9, P< 0.0001). There were 52 cases in
the intent-to-treat analysis in the pneumococcal
group, for an effectiveness of 93.9% (95%
CI¼ 79.6–98.5, P< 0.001) [47].
Efficacy against pneumonia
The impact of vaccination on pneumonia was
evaluated by different categories based on clinical
and/or radiologic diagnosis. Vaccine efﬁcacy for
clinically diagnosed pneumonia was 11.4% (range
1.3–21%). The efﬁcacy was better when there was a
radiologic abnormality suggestive of pneumo-
nia—33% (range 7.5–52%). When efﬁcacy was
evaluated for the classic pneumonia with large
pulmonary consolidation (> 2.5 cm), efﬁcacy in-
creased to 73% (range 38–88%) [47]. These efﬁcacy
results conﬁrm that pneumococci are responsible
for many more cases of pneumonia than those
associated with the classical lobar consolidation,
commonly attributed to the pneumococcus on
chest radiographs.
Otitis media
The seven-valent pneumococcal conjugate vaccine
in the Kaiser Permanente study had efﬁcacies as
follows: against otitis media visits, 8.9%; against
acute otitis media episodes, 7%; and against recur-
rent episodes, 9.3%. It also gave a 20% reduction in
ventilatory tube placement [47]. In the USA, acute
otitis media is an important cause of clinical con-
sultation, with an annual cost of over $5 billion,
and a small reduction in the incidence of disease
could result in substantial annual savings [23].
An etiology-speciﬁc study of otitis media from
Finland evaluated the efﬁcacy of the same vaccine.
In this study, 1662 infants were recruited and
offered vaccination at 2, 4, 6 and 12months of
age. Etiologic diagnosis of acute otitis media
was made by tympanostomy. There was a 57%
(range 44–67%) reduction in the incidence of dis-
ease caused by pneumococcal serotypes included
in the vaccine. Prevention of otitis media irrespec-
tive of etiology was 6% (range 4–16%) [55].
In the Finnish trial, the impact of vaccination on
the total number of otitis media episodes, regard-
less of etiology, was not statistically signiﬁcant, at
6% (95% CI¼ 4–16%), whereas in the California
study, there was a statistically signiﬁcant 7%
reduction (95% CI¼ 4–10).
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RECOMMENDATIONS FOR USE
The basis of the recommendations for use of the
seven-valent pneumococcal vaccine is conferment
of protection at the earliest possible opportunity
for the young infant. Newborn infants should
begin the schedule at 2months, although the vac-
cine can be administered as early as 6weeks [56].
Three doses are offered at 2-month intervals,
with a booster between 12 and 15months of age.
All children aged 23months should be vacci-
nated using the schedule shown in Table 1.
Although formal efﬁcacy data are lacking for
clinical conditions that are known to predispose to
invasive pneumococcal disease, the use of the
vaccine has been recommended. Safety and immu-
nogenicity of some of the pneumococcal conjugate
vaccines have been established in sickle cell dis-
ease [57] and HIV infection [58,59]. Thus it is
recommended that vaccination should be offered
to children who have underlying medical condi-
tions or are immunocompromised and at risk of
pneumococcal disease. These include children
who have sickle cell hemoglobinopathy, functional
or anatomic asplenia, chronic pulmonary disease,
diabetes mellitus, cerebrospinal ﬂuid leak, HIV
infection, lymphomas, or leukemia, and those
who have undergone immunosuppressive ther-
apy or solid organ transplantation (Table 2).
In addition to these conditions, The Advisory
Committee on Immunization Programs (ACIP) in
the USA recommends that all children between 24
and 59months of age should be considered for
vaccination, with special priority given to the
category of children listed in Table 3.
IMPACT OF VACCINATION ON
NASOPHARYNGEAL CARRIAGE OF
PNEUMOCOCCI
The effect of widespread use of a pneumococcal
conjugate vaccine is as yet unknown. Unlike H.
inﬂuenzae type b, S. pneumoniae is diverse, and
there are concerns that following widespread
use of the vaccine in a population, immune pres-
sure may induce capsular transformation or repla-
cement in the nasopharynx by non-vaccine
serotypes, with a consequent emergence of disease
caused by non-vaccine serotypes [60,61]. There is
already evidence that, following vaccination with
the conjugate vaccine, there is a reduction in the
nasopharyngeal carriage of serotypes included in
the vaccine, and an increase in carriage of non-
vaccine serotypes has also been reported in some
studies [44,54]. It was initially not clear whether
this observation would translate into an increase
in disease incidence. However, the otitis media
studies from Finland reported an increase in inci-
dence of disease caused by non-vaccine serotypes
[55]. Thus, there is a need to continuously monitor
the epidemiology of disease after introduction of
the vaccine into any population. A community
randomized study of the seven-valent pneumo-
coccal conjugate vaccine in Native Americans
has just been completed [62]. This study will hope-
fully give insight into the potential impact of
Table 1 Recommended schedule for use of seven-valent pneumococcal conjugate vaccine among previously vaccinated
infants and children by age at time of first vaccination
Age at first dose (months) Primary series (interval in months) Additional dose
2–6 3 doses (2)a 1 dose at 12–15 months
7–11 2 doses (2)b 1 dose at 12–15 months
12–23 2 doses (2)c –
24–59
Healthy children 1 dose –
Children with sickle cell
disease, asplenia, human
immunodeficiency virus
infection, chronic
illness or
immunocompromising
conditiond
2 doses (2) apart
aFor children vaccinated at age <1 year, minimum interval between doses is 4weeks.
bThe additional dose should be administered >8weeks after the primary series has been completed.
cMinimum interval between doses is 8weeks.
dRecommendations do not include children who have undergone a bone marrow transplantation.
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vaccination of a community on the epidemiology
of pneumococcal disease.
IMPACT OF VACCINATION ON
ANTIBIOTIC-RESISTANT
PNEUMOCOCCI
Pneumococci of serogroups 6, 14, 19 and 23 are
often carried in the nasopharynx of children, and
these acquire resistance most frequently. Indiscri-
minate and frequent prescription of antibiotics to
children have contributed to the global escalation
of antibiotic resistance. Data from Israel [63] sug-
gest that a multivalent pneumococcal conjugate
vaccine may reduce the carriage and spread of
these pneumococci, particularly in daycare cen-
ters. However, this should bemonitored closely, as
it is possible that, by horizontal gene transfer,
antibiotic resistance genes may be transferred to
non-vaccine serotypes.
ADDITIONAL EFFICACY STUDIES
The efﬁcacy of this vaccine has been remarkable
against invasive and non-invasive disease syn-
dromes. However, additional clinical trials to
assess efﬁcacy of the same or similar vaccine for-
mulations in different populations are needed.
Limited studies have been conducted in HIV-
infected subjects, and these have demonstrated
encouraging immunogencity results [58,59], but
efﬁcacy also needs to be determined in popula-
tions with a high prevalence of HIV, where the risk
of invasive pneumococcal disease is several times
higher. It is against this background that the study
in South Africa is being conducted, and this is near
completion. A further study to evaluate the efﬁ-
cacy of the vaccine is in progress in a rural popula-
tion in the Gambia, where there is a high
prevalence of malaria and high infant mortality.
FUTURE DEVELOPMENTS
The development and licensure of the PCV7 has
been a major breakthrough in the control of inva-
sive pneumococcal disease. However, one major
limitation with protein conjugation of pneumococ-
cal polysaccharide is the number of serotypes that
can be included in a vaccine formulation because
of manufacturing considerations and cost of pro-
duction. For optimal efﬁcacy, vaccine composition
will be determined by the prevalent pneumococcal
serotypes in a given region, and the target group.
Table 2 Summary of recommendations for the use of seven-valent pneumococcal conjugate vaccine (PCV7) among infants
and children
Children for whom PCV7 is recommended
All children aged 23months
Children aged 24–59months with the following conditions:
Sickle cell disease and other sickle cell hemoglobinopathies, congenital or acquired asplenia, or splenic dysfunction
Infection with human immunodeficiency virus
Immunocompromising conditions including: congenital immunodeficiencies—B-(humoral) or T-lymphocyte deficiency;
complement deficiencies, particularly c1, c2, c3 and c4 deficiency; and phagocytic disorders, excluding chronic
granulomatous disease
Renal failure and nephritic syndrome
Diseases associated with immunosuppressive therapy or radiation therapy, including malignant neoplasms, leukemias,
lymphomas, and Hodgkin’s disease; or solid organ transplantation
Chronic illness, including:
1. Chronic cardiac disease, particularly cyanotic congenital heart disease and cardiac failure
2. Chronic pulmonary disease, excluding asthma unless on high-dose corticosteroid therapy
3. Cerebrospinal fluid leaks
4. Diabetes mellitus
Table 3 Children for whom PCV7 should be considered
(based on ACIP recommendations in the USA)
All children aged 24–59months, with priority given to:
Children aged 24–35 months
Children of Alaskan Native or Native American descent
Children of African-American descent
Children who attend group daycare centersa
aDefined as a setting outside the home where a child
regularly spends 4 h/week with 2 unrelated children
under adult supervision.
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The threat of a change in the epidemiology of
pneumococcal disease following the introduction
of pneumococcal conjugate vaccine is a reason to
continue active surveillance of disease. Further-
more, such surveillance will provide information
about trends in antimicrobial resistance, and
potential herd immunity, and will allow more
comprehensive reports of vaccine-related health
events.
Although several high-risk groups for invasive
pneumococcal disease are well recognized, formal
evaluations of the efﬁcacy of this vaccine in such
groups are required so that their use can be opti-
mized.
The current unit cost of a glycoprotein conjugate
vaccine may prohibit its use in areas where it is
most needed—developing countries. If the ulti-
mate goal is to achieve global control of invasive
pneumococcal disease, it is imperative that vac-
cines are made available at subsidized rates to
developing countries.
Control of neonatal and early infant disease
The proposed immunization schedule for the pro-
tein conjugate pneumoccocal vaccine in develop-
ing countries is likely to be a three-dose schedule
given at 2, 3 and 4months or 6, 10 and 14weeks
with DPT. However, because children in develop-
ing countries are frequently late in presenting for
immunization, it is likely that infants given the
conjugate vaccine may not be protected until they
reach the age of 4–5months. In developing coun-
tries, by the age of 5months, as many as 20% of
cases of invasive pneumococcal disease in infants
would have occurred [27,64]. Although a strong
herd effect, resulting from widespread vaccine
use, may decrease the incidence of pneumococcal
disease in infants too young to be vaccinated, as
was observed following the introduction of Hib
vaccines, the outcome with these multiserotype
bacteria is less predictable. A possible approach
to this problem lies in the combination of maternal
immunization during pregnancy with active
immunization during infancy, an approach that
works effectively in the prevention of tetanus.
Another alternative approach to control the bur-
den of pneumococcal disease in the ﬁrst 3 months
of life is neonatal immunization with protein con-
jugate pneumococcal vaccines. Results of neonatal
immunization studies with Hib conjugate vaccine
based on the protein carriers tetanus toxoid and
CRM197 are encouraging, but this approach has not
been evaluated for the pneumococcal conjugate
vaccines.
Duration of protection
The duration of protection following vaccination is
not known. It is assumed that because the vaccine
induces immunologic memory, immune protec-
tion is likely to last for a long time, possibly for
life. However, this is not known for sure. It is, in
fact, not clear at this stage if a fourth dose, as
recommended by the current schedule in infancy,
will be required in all settings.
Correlates of immune protection
Currently, immunogenicity is measured by using
ELISA methods to determine serotype-speciﬁc
antibody concentrations. It is still not known, how-
ever, what concentration confers immunity. Func-
tional tests such as opsonophagocytosis and
avidity indices are being evaluated, but there is
still a need to establish an immune correlate of
clinical protection. Such validated immune system
correlates will be invaluable in the evaluation of
new vaccines against pneumococcal infections.
Combination vaccines
In most developing countries, the immunization
schedule during the ﬁrst year of life already
involves about 8–10 injections, and there are con-
cerns that an additional injectionmay compromise
participation in immunization programs. In order
to improve delivery and reduce cost, research into
combinations of vaccines has been given much
attention recently. Thus, vaccine manufacturers
have developed different vaccine formulations
that combine other already licensed vaccines with
new antigens.
The multiplicity of the pneumococcal serotypes
has also encouraged the development of newer
approaches that would incorporate more sero-
types into a vaccinewithout antigenic interference.
There are studies that have evaluated the use of
different carrier proteins for different pneumococ-
cal serotypes in the same vaccine, but results of the
serotype-speciﬁc antibody responses have been
lower than those reported with single protein
carrier formulations [65]. Since the concentration
of serotype-speciﬁc antibody that is protective is
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not known, it has been difﬁcult to interpret these
ﬁndings.
CONCLUSION
The availability of the technology to induce immu-
nogenicity in young infants to pneumococcal poly-
saccharides and to offer protection against disease
by the serotypes contained in the vaccine is a giant
leap in the progress towards the control of pneu-
mococcal disease worldwide. However, the effort
must be sustained, and the current concerns about
the limitations of pneumococcal conjugate vac-
cines should encourage the development of new
vaccines using species-common, genetically con-
served pneumococcal proteins, either in combina-
tion or as a conjugate for the pneumococcal
polysaccharide, and there are now several
encouraging results, albeit at preliminary stages
of development.
Unfortunately, because the diagnostic tools for
pneumococcal disease are not very sensitive, the
true burden of pneumococcal disease may not be
fully appreciated until the vaccines are widely
introduced and the incidences of disease syn-
dromes are analyzed before and after the intro-
duction of vaccination—an important issue to be
brought to the attention of health planners and
policy-makers.
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